Contraindications to PCSK9 Inhibitors
The only absolute contraindication to PCSK9 inhibitors (evolocumab, alirocumab, and inclisiran) is a history of serious hypersensitivity reaction to the specific agent or any of its excipients.
Absolute Contraindications
According to FDA labeling, each PCSK9 inhibitor is contraindicated in patients with prior serious hypersensitivity reactions 1, 2, 3:
- Evolocumab (Repatha): History of serious hypersensitivity to evolocumab or excipients
- Alirocumab (Praluent): History of serious hypersensitivity to alirocumab or excipients (including hypersensitivity vasculitis, angioedema, and reactions requiring hospitalization)
- Inclisiran (Leqvio): Prior serious hypersensitivity to inclisiran or excipients
Important Clinical Considerations (Not Absolute Contraindications)
Pregnancy and Lactation
All lipid-lowering drugs, including PCSK9 inhibitors, should be avoided during pregnancy, nursing, or in women who may become pregnant 4. Lifestyle interventions can be considered as general management for dyslipidemia during these periods.
Homozygous Familial Hypercholesterolemia with Minimal LDL Receptor Activity
PCSK9 inhibitors are not recommended (though not formally contraindicated) in patients with negative/negative LDLR mutations having LDL receptor activity below 2%, as some level of LDL receptor activity is required for efficacy 5. This is based on evidence from the TESLA B and TAUSSIG studies.
Key Differentiating Features
Unlike statins and ezetimibe, PCSK9 inhibitors have remarkably few contraindications:
- No hepatic impairment concerns (unlike ezetimibe which is not recommended in moderate/severe hepatic impairment 6)
- No clinically significant drug-drug interactions identified for alirocumab or evolocumab 7
- No renal dose adjustments required, though evidence is more limited in advanced CKD stages 4-5 and ESRD 8
Practical Pitfalls to Avoid
The most common clinical error is confusing relative contraindications or precautions with absolute contraindications. PCSK9 inhibitors have an exceptionally clean safety profile with minimal absolute contraindications compared to other lipid-lowering agents 9. The primary barrier to use is typically cost and access rather than medical contraindications 4.
Storage requirements (refrigeration at 2-8°C) and subcutaneous administration are practical considerations but not contraindications 4.